CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 10-Q | 2026-05-15 | English | |
| FORM 8-K | 2026-05-14 | English | |
| 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | |
| 424B4 | 2026-05-13 | English | |
| Regulatory Filings 2026 | 2026-05-12 | English | |
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46362719 | FORM 10-Q | 2026-05-15 | English | ||
| 46274090 | FORM 8-K | 2026-05-14 | English | ||
| 45766521 | 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | ||
| 46081758 | 424B4 | 2026-05-13 | English | ||
| 46081745 | Regulatory Filings 2026 | 2026-05-12 | English | ||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 46081761 | DEL AM | 2026-04-24 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
2 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
QUIA PHARMA AB
Develops medicines using a proprietary drug delivery platfo…
|
QUIA | SE | Professional, scientific and te… |
|
Qurient Co., Ltd.
Clinical-stage biopharma developing drugs for oncology, cGv…
|
115180 | KR | Professional, scientific and te… |
|
RACURA ONCOLOGY LTD
Clinical-stage developer of precision oncology therapeutics…
|
RAC | AU | Professional, scientific and te… |
|
RADIOPHARM THERANOSTICS LIMITED
Clinical-stage company developing radiopharmaceutical produ…
|
RAD | AU | Professional, scientific and te… |
|
Radiopharm Theranostics Ltd
Clinical-stage company developing radiopharmaceuticals for …
|
RADX | US | Professional, scientific and te… |
|
Rafael Holdings, Inc.
Invests in and develops therapies for cancer and rare genet…
|
RFL | US | Professional, scientific and te… |
|
Rain Enhancement Technologies Holdco, Inc.
Develops ionization-based weather modification technology f…
|
RAIN | US | Professional, scientific and te… |
|
Rakovina Therapeutics Inc.
Biopharma developing targeted cancer treatments using AI to…
|
RKV | CA | Professional, scientific and te… |
|
Rallybio Corp
A clinical-stage biotech company developing therapies for s…
|
RLYB | US | Professional, scientific and te… |
|
RaQualia Pharma Inc.
Develops and out-licenses innovative small molecule drug co…
|
4579 | JP | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.